after giving informed consent, you will attend an initial visit where a series of questionnaires and clinical scales are completed. these include a symptom rating called panss, a mood questionnaire, and quality‑of‑life measures. blood samples may be taken for future analysis. this visit establishes the baseline values that will be compared later.

based on a computer‑generated random list, you will be assigned to receive either cannabidiol or a matching placebo. the assignment is double‑blind, meaning neither you nor the study staff will know which product you receive.

you will begin taking one dose each day for a total of six weeks. the active product contains 1000 mg of cannabidiol taken by mouth (oral route). the placebo looks identical but contains no active substance. you will continue your regular antipsychotic medication throughout this period.

you will attend short clinic visits at week 2, week 4, and week 6. during each visit, safety checks such as blood pressure and heart rate are performed, and the same symptom questionnaires used at baseline are repeated. any side effects are recorded and reported.

at the end of the six‑week period (week 6), a final set of assessments is completed. the change in the panss score from baseline is the primary measure of improvement. additional questionnaires on mood, anxiety, and quality of life are also collected.

after the treatment period, you may be invited to return for additional assessments at later times to evaluate longer‑term outcomes. participation in these follow‑up visits is voluntary.